ARQT
ARQT
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
62
$19.64M
Total Volume
$19.64M
100 transactions
Net Activity
$19.64M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Watanabe Todd
See Remarks
$5.50M total
Matsuda Masaru
EVP, GC
$3.95M total
Welgus Howard G.
Dir
$2.71M total
Burnett Patrick
See Remarks
$2.09M total
Leonard Keith R
Dir
$997K total
Quick Actions
ARQT has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. ARQT ranks #318 in insider activity out of 563 tracked companies in its industry.
Over the last 90 days, corporate insiders at ARQT (ARQT) engaged in a total of 100 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 62 were sales. The total volume of insider trading reached $19.64M.
The net insider activity for ARQT shows a net selling bias of $19.64M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Watanabe Todd (See Remarks), who traded 50.0K shares valued at $1.52M on Nov 21, 2025.
Arcutis Biotherapeutics (ARQT) Stock Trades At A Discount To Sales But Fair Value Looks Tight
Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain?
Arcutis Biotherapeutics (ARQT) Heads Into Earnings With Its ZORYVE Story Still Shaping Valuation
Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb
FAQs About ARQT Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ARQT.